Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes
Wade T. Iams(Vanderbilt University Medical Center), Christine M. Lovly(Dana-Farber Cancer Institute), Catherine B. Meador(Vanderbilt University Medical Center), Joseph T. Schneider(Vanderbilt University Medical Center), Eileen Shiuan(Vanderbilt University), Marc Roth(Vanderbilt University), Jeremy L. Warner(Vanderbilt University Medical Center), Christine Vaupel(Navidea Biopharmaceuticals (United States)), IlaSri B. Summitt(Navidea Biopharmaceuticals (United States)), Zhiguo Zhao(Vanderbilt University), Lucy Lu Wang(Vanderbilt University Medical Center), Kelli L. Boyd(Vanderbilt University Medical Center), Jennifer Bordeaux(Yale University)
Cited by 76
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Mechanisms of receptor tyrosine kinase activation in cancer
|Molecular Cancer|2018|1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
Antibody validation
|BioTechniques|2010|595